[1]HAN B,ZHENG R,ZENG H,et al.Cancer incidence and mortality in China,2022[J].Journal of the National Cancer Center,2024,4(1):47-53.
[2]DOCHERTY JR.The pharmacology of α1-adrenoceptor subtypes[J].European Journal of Pharmacology,2019,855:305-320.
[3]KAMIAR A,YOUSEFI K,DUNKLEY JC,et al.β2-Adrenergic receptor agonism as a therapeutic strategy for kidney disease[J].American Journal of Physiology-Regulatory,Integrative and Comparative Physiology,2021,320(5):R575-R587.
[4]PADRO CJ,SANDERS VM.Neuroendocrine regulation of inflammation[J].Seminars in Immunology,2014,26(5):357-368.
[5]LI Z,LIN Y,SONG H,et al.First small-molecule PROTACs for G protein-coupled receptors:inducing α1A-adrenergic receptor degradation[J].Acta Pharmaceutica Sinica.B,2020,10(9):1669-1679.
[6]EFESOY O,SAYLAM B,TEK M,et al.Is there any priority between the alpha blockers on voiding functions after transrectal ultrasound guided prostate biopsy[J].Turkish Journal of Urology,2021,47(2):137-143.
[7]SUN X,YANG S,SONG W.Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1[J].Biomedicine & Pharmacotherapy,2020,124:109731.
[8]SPENCER BH,MCDERMOTT CM,CHESS-WILLIAMS R,et al.Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel[J].Pharmacology,2018,102(1-2):10-18.
[9]AN M,MA WH,JIA HW,et al.Prazosin inhibits the growth and mobility of osteosarcoma cells[J].Translational Cancer Research,AME Publishing Company,2019,8(5):1997-2004.
[10]BROSO F,GATTO P,SIDAROVICH V,et al.Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation[J].Cancer Research,2023,83(16):2733-2749.
[11]KING L,CHRISTIE D,DARE W,et al.Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment:From bench to bedside[J].European Journal of Pharmacology,2021,893:173831.
[12]FLORENT R,POULAIN L,N'DIAYE M.Drug repositioning of the α1-adrenergic receptor antagonist naftopidil:A potential new anti-cancer drug[J].International Journal of Molecular Sciences,2020,21(15):5339.
[13]HUAN HB,WEN XD,CHEN XJ,et al.Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells[J].Brain,Behavior,and Immunity,2017,59:118-134.
[14]LIU D,XU X,DAI Y,et al.Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment[J].Journal for ImmunoTherapy of Cancer,2021,9(1):e001466.
[15]YUKI K.The immunomodulatory mechanism of dexmedetomidine[J].International Immunopharmacology,2021,97:107709.
[16]PEREZ PC,RIVERO EM,GARGIULO L,et al.Adrenergic receptors in breast cancer[J].Progress in Molecular Biology and Translational Science,2022,193(1):37-63.
[17]WANG C,DATOO T,ZHAO H,et al.Midazolam and dexmedetomidine affect neuroglioma and lung carcinoma cell biology in vitro and in vivo[J].Anesthesiology,2018,129(5):1000-1014.
[18]ZHU J,NAULAERTS S,BOUDHAN L,et al.Tumour immune rejection triggered by activation of α2-adrenergic receptors[J].Nature,2023,618(7965):607-615.
[19]WANG K,WU M,XU J,et al.Effects of dexmedetomidine on perioperative stress,inflammation,and immune function:systematic review and meta-analysis[J].British Journal of Anaesthesia,2019,123(6):777-794.
[20]JUN JH,SHIM JK,OH JE,et al.Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model[J].Scientific Reports,2023,13(1):12471.
[21]CARNET LE PROVOST K,KEPP O,KROEMER G,et al.Trial watch:dexmedetomidine in cancer therapy[J].Oncoimmunology,2024,13(1):2327143.
[22]XING XW,SUN YF,ZHAO J,et al.Tizanidine hydrochloride exhibits a cytotoxic effect on osteosarcoma cells through the PI3K/AKT signaling pathway[J].The Journal of International Medical Research,2019,47(8):3792-3802.
[23]MACCARI S,BUONCERVELLO M,ASCIONE B,et al.α-Adrenoceptor stimulation attenuates melanoma growth in mice[J].British Journal of Pharmacology,2022,179(7):1371-1383.
[24]PADRO CJ,SANDERS VM.Neuroendocrine regulation of inflammation[J].Seminars in Immunology,2014,26(5):357-368.
[25]HARA MR,KOVACS JJ,WHALEN EJ,et al.A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1[J].Nature,2011,477(7364):349-353.
[26]AMMONS DT,MACDONALD CR,CHOW L,et al.Chronic adrenergic stress and generation of myeloid-derived suppressor cells:Implications for cancer immunotherapy in dogs[J].Veterinary and Comparative Oncology,2023,21(2):159-165.
[27]GLOBIG AM,ZHAO S,ROGINSKY J,et al.The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion[J].Nature,2023,622(7982):383-392.
[28]HULSURKAR M,LI Z,ZHANG Y,et al.Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1[J].Oncogene,2017,36(11):1525-1536.
[29]COELHO M,SOARESSILVA C,BRANDAO D,et al.β-Adrenergic modulation of cancer cell proliferation:available evidence and clinical perspectives[J].Journal of Cancer Research and Clinical Oncology,2017,143(2):275-291.
[30]ZHANG D,MA Q,WANG Z,et al.β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway[J].Molecular Cancer,2011,10:146.
[31]ZHANG X,ZHANG Y,HE Z,et al.Chronic stress promotes gastric cancer progression and metastasis:an essential role for ADRB2[J].Cell Death & Disease,2019,10(11):788.
[32]COELHO M,MOZ M,CORREIA G,et al.Antiproliferative effects of β-blockers on human colorectal cancer cells[J].Oncology Reports,2015,33(5):2513-2520.
[33]ZABOROWSKASZMIT M,SZMIT S,OLSZYNASEREMENTA M,et al.Beta blockers with statins may decrease all-cause mortality in patients with cardiovascular diseases and locally advanced unresectable non-small-cell lung cancer after chemoradiotherapy[J].Cancers,2023,15(4):1277.
[34]OH MS,GUZNER A,WAINWRIGHT DA,et al.The impact of Beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors[J].Clinical Lung Cancer,2021,22(1):e57-e62.
[35]FAROOQ MA,AJMAL I,HUI X,et al.β2-adrenergic receptor mediated inhibition of T cell function and its implications for CAR-T cell therapy[J].International Journal of Molecular Sciences,2023,24(16):12837.
[36]YAN X,LIU P,LI D,et al.Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors[J].International Immunopharmacology,2022,113:109383.
[37]SHI DD,GUO JA,HOFFMAN HI,et al.Therapeutic avenues for cancer neuroscience:translational frontiers and clinical opportunities[J].The Lancet Oncology,2022,23(2):e62-e74.
[38]WU FQ,FANG T,YU LX,et al.ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α[J].Journal of Hepatology,2016,65(2):314-324.
[39]CHANG CH,LEE CH,KO JC,et al.Effect of β-blocker in treatment-naive patients with advanced lung adenocarcinoma receiving first-generation EGFR-TKI[J].Frontiers in Oncology,2020,10:583529.